Floatz logo

N-Desmethyl-4-Hydroxytamoxifen

Desmoid Tumor

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Desmoid Tumor cohort.

Asset / SponsorPhaseRating
Nivolumab
Parabilis Medicines, Inc.
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Fog-001
Parabilis Medicines, Inc.
Phase 1/2CCC
Tipiracil
Parabilis Medicines, Inc.
Phase 1/2CCC
Tegavivint
Children's Oncology Group
Phase 1/2CCC
Trifluridine
Parabilis Medicines, Inc.
Phase 1/2CCC
Fes F-18
Vanderbilt-Ingram Cancer Center
Early Phase 1C

Same molecule, other indications

N-Desmethyl-4-Hydroxytamoxifen is also rated in:

bipolar I disorderDormant
B
Indicative · Phase 3
60 / 100
View asset →
angiosarcomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
ductal breast carcinoma in situActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →